Pharma Journalist

Cytokine-Based Drug Development Summit
2022-07-26 - 2022-07-29 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The 3rd Cytokine-Based Drug Development Summit has been developed following extensive research to address YOUR biggest challenges in the cytokine field.
With 30+ expert speakers, including the hottest academic researchers and leading figures from the industry, this 4-day program is your opportunity to gain insight into the latest clinical advancement and have thought provoking discussions around how to overcome the fields greatest drug development challenges.
What can you expect to see?

Further your understanding of the underlying mechanisms of action, and T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Ask-Gene Pharma
Optimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Proviva Therapeutics
Leverage insights from industry’s leading lights to overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with Equilium, Cytonus Therapeutics & Cytimmune
Take a deep dive into preclinical cancer models covering both in vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with Astra Zeneca & Xilio Therapeutics
Uncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies with Alkermes & NeoImmune Tech

Get your copy of the brand-new agenda for the full list of speakers and sessions.

2nd Annual mRNA-Based Therapeutics Summit
2022-07-26 - 2022-07-28 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Do you want to be part of the largest gathering of mRNA professionals?
The 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28.
Expect exclusive data from the movers and shakers in mRNA vaccine and therapy development, 75+ world-class speakers, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m
Here’s a snapshot of the expert speakers you can hear from:

​​​​Kathy Fernando, VP, Head of Worldwide Research, Development and Medical Operations & Head of mRNA Scientific Planning, Pfizer
Regis Gervier, Global Head, mRNA Center of Excellence, Sanofi
Rituparna Das, VP – COVID Vaccines, Moderna
Hao Chen, Global Head of Cell & Viral Drug Substance, GlaxoSmithKline
Joe Payne, Founder, President & CEO, Arcturus Therapeutics
Pervin Anklesaria, Deputy Director, HIV Vaccines & Biologics, Bill & Melinda Gates Foundation
Manmohan Singh, SVP – Pharmaceutical Sciences & Delivery Technologies, Beam Therapeutics
Akhilesh Bhambhani, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops, Ultragenyx
Liang Shang, Senior Scientist – Vaccine Analytical, Merck
Russell Johnson, VP – Formulation Research, RVAC Medicines
Tamar Grossman, Global Head – RNA & Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson

Download the official brochure to discover why Sanofi, Ultragenyx, Beam Therapeutics, Pfizer, Moderna, Merck, Eli Lilly, GSK, and 300+ others have already secured their places. https://ter.li/yc800m

iPSC Manufacturing Summit
2022-07-26 - 2022-07-28 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients.
This forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products, with in depth case studies aimed to develop optimal differentiation, cryopreservation, and analytical protocol to enhance process development to ensure it is robust, rapid and repeatable.
Our 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization, enhance iPSC product quality, and integrate successful gene-editing into your manufacturing.
Take a look at the full event guide to learn more.

Targeted Radiopharmaceuticals Summit US (TRP US)
2022-07-26 - 2022-07-28 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months, with a wave of new investment in light of Lutathera’s extraordinary performance.
Are you part of a pharmaceutical business aiming to have their Theranostic approved? If so, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging.
Hear the latest insights, case studies, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.
To know more visit: https://ter.li/jtzz4q

Cell Therapy Analytical Development Summit Europe
2022-08-23 - 2022-08-25 | Hilton London Paddington, 146 Praed St, London, W2 1EE, United Kingdom
Cell Therapy Analytical Development Summit Europe, taking place from 23-25 of August in London, will bring together professionals working in CMC, QC, process development, and regulatory functions.
Join your peers in person to:

Learn to develop a successful potency assay to determine product activity
Explore reference standards for state-of-the-art analytical development
Discover new technology to expand and improve your analytical toolbox
Develop and validate analytical methods to fulfil GMP guidelines
Streamline final product characterisation by starting with the end in mind

You can view the event guide here: https://ter.li/nxuxfd
Secure your place at the summit here: https://ter.li/551w6c
We are looking forward to welcoming you to London this August!

6th IPF Summit
2022-08-29 - 2022-09-01 | Westin Boston Seaport District, 425 Summer St, Boston, MA, 02210, United States
With two approved therapeutics and the field working to develop the next generation of IPF drugs, the opportunity to become the undisputed, most effective, and disease-modifying agent on the market has never been greater.
From repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development.
What’s new and unmissable for 2022:

29 brand new industry speakers, as well as returning KOLs including Fernando Martinez, Naftali Kaminski, Toby Maher, and many more
6 interactive workshops to delve into IPF’s hottest topics, discuss challenges, pose your burning questions to leading experts, and highlight the respiratory pipeline development opportunities including SSc-ILD, COPD, and COVID fibrosis
A brand-new Tissue Repair and Regeneration Day, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities
Exclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development

Get in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie, Boehringer Ingelheim, Bayer, BMS, Genentech, Galecto, Novartis, and Trevi Therapeutics.
From navigating pathophysiology and pathobiology, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research.
To know more visit: https://ter.li/6yo2nd

2nd Integrin-Targeted Drug Development Summit
2022-08-30 - 2022-09-01 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Over the last 12 months, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma, Corbus Pharmaceuticals, Vincerx, and Morphic are paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.
In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.
Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases.
Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.
To know more visit: https://ter.li/qoq74v

Optimizing AAV Safety Summit
2022-09-06 - 2022-09-08 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose!
In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.
Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.
To know more visit: https://ter.li/r92wow

5th International Cannabinoid-Derived Pharmaceuticals Summit
2022-09-06 - 2022-09-08 | Boston, MA (venue TBC)
Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials and multimillion-dollar deals. Right now, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3, pushing for approval to meet the clinical needs of patients with chronic pain, cancer, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap, funding and changing regulation – to name just a few.
The 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers, investors, solution providers and academics from around the globe working to overcome these challenges and progress the field of cannabinoid therapeutics. 35+ expert speakers will lead sessions on critical topics across 3 days of presentations, panel discussions and interactive workshops in Boston.
Agenda highlights include:

Present a poster of your drug development pipeline at our investor networking session, and connect with the decision makers looking to fund promising cannabinoid therapeutics
Get the most up-to-date regulatory perspectives from the FDA and other organizations with Dominic Chiapperino (FDA) and Cassie Taylor
(FDA)
Produce and source high-purity cannabinoids from synthetic, plant-based and biosynthetic sources with Purisys, Kinetochem and our other world-leading partners
Hear from the key opinion leaders at the forefront of next-generation cannabinoid-derived pharmaceutical development including Alistair Vickery (Emyria), Brian Murphy (Former CEO of Emerald Bioscience) and Jeff Chen (Radicle Sciences)
Streamline successful late-stage clinical trials and be the next one across the finish line with a multi-format and highly interactive session with Sud Agarwal (Cannvalate)
Join 2 half-day workshops – one dedicated to bridging the gap between OTC and prescribed pharmaceuticals, and an additional behind-the-scenes workshop on the psychedelics field, preparing you for exploration into a new area
Connect with 80+ thought leaders and industry peers as they come together to drive discussion and progress across the 3-day event

The Summit focuses on the real science in the cannabinoid industry and is the only chance to connect with likeminded, analytical professionals looking to move the dial forward in this exciting space. Check out the event guide for the full agenda

3rd Annual Gene Therapy for Ophthalmic Disorders
2022-09-13 - 2022-09-16 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
Revolutionizing Genetic Therapy Development & Delivery to the Eye
Discovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches
The ophthalmology field is bursting with novel genetic approaches for targeting many disorders, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic, as well as more innovative outpatient methods such as suprachoroidal delivery, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders.
Returning for its 3rd year, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges, with focus on discussing and sharing solutions with the key leaders in the industry.
This year we have expanded into two streams of learning, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development.
Gene therapy for ophthalmic disorders has only seen one FDA approved therapy, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market.
Leave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.

5th Microbiome Movement – Skin Health & Dermatology Summit
2022-09-13 - 2022-09-15 | Four Points by Sheraton Boston Logan Airport Revere, 407 Squire Rd, Revere, MA, 02151, United States
Translating Scientific Methodologies Addressing the Skin Microbiome into Commercially Viable Dermatological Therapeutics & Cosmetic Products
Skin microbiome research is continuing to gain increasing market traction from a number of stakeholders, including drug developers and cosmetic brands. For investment and progress to continue, it is vital to meet and connect with the key opinion leaders in the space.
Now in its fifth year, the Microbiome Movement – Skin Health & Dermatology Summit will unite the field’s leaders from academia and industry to address the unique scientific and commercial challenges of working in the skin microbiome. This meeting will provide a platform for crucial discussions which will hasten the development of microbiome-targeting therapeutics and cosmetics that focus on characterization, clinical testing, and product commercialization.
This is your opportunity to connect with 100+ collaborative thought leaders in the skin microbiome field from academics, drug developers, cosmeceutical developers, cosmetic and consumer brands, to obtain a holistic view of the microbiome dermatology landscape that will revolutionise your product pipeline.
Find out more about the meeting, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/nzhrvy
Or become one of our event partners and showcase your company’s latest technologies and solutions! Get in touch with us directly or request a partnership prospectus here: https://ter.li/9kybuv
We look forward to welcoming you to Boston in September!

7th CAR-TCR Summit
2022-09-19 - 2022-09-23 | Boston, MA
Back to Boston with a bang! With 1,500 CAR and TCR developers, 200 speakers, 150 live presentations, 20 hours of networking and more surprises in store, the 7th CAR-TCR Summit will be the BIGGEST ever.
Gain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein.
Discuss everything from novel allogeneic approaches with enhanced safety considerations, the latest in vivo gene engineering techniques, and advances in CMC and analytics to ensure the development of high-quality cell products.
With your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms, learnings from our successes and pitfalls, and manufacturing automation innovations for large scale consistent production, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers, more content and more exclusive insights than ever before!
To know more visit: https://ter.li/km5zwy

2nd Annual Aseptic Processing Conference
2022-09-19 - 2022-09-20 | London, UK
2nd Annual Aseptic Processing Conference
Conference: 19 – 20 September 2022
Workshop: 21 September 2022
London, UK
http://www.asepticprocessing.co.uk/PJWL

Sponsored by: Dec Group, Rapid Micro Biosystems, Raumedic and STERIS

Conference Chairman: James Drinkwater, Head of Aseptic Processing Special Interest Group PHSS and Head of GMP Compliance, F Ziel GMBH
Driving a Holistic Approach to Assurance of Product Sterility through Aseptic Manufacturing following QRM Principles
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference, this year taking place in London, on the 19 and 20 September 2022.
The Aseptic processing industry has seen consistent growth in recent years, with advances in innovative therapeutics, the introduction of novel techniques and personnel protocols, the integration of robotics and automation in filling lines, and rise of rapid microbiological methods being just a few of the factors driving this growth.
The Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015, and is projected to exceed 12 billion USD in value by next year, then to far surpass a total market value of 50 billion USD before the end of the decade.
Join us to discuss and address the Guidance and Regulation including the EU GMP Annex 1, environmental control delving into the contamination control strategy, Pharma moving forward 4.0 covering data integrity and data consistency, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring
This event is CPD Accredited
Event Hashtag: #AsepticProcessing
Benefits of Attending:

Discuss the revisions and the impact of Annex 1 on aseptic manufacturing
Explore the applications of rapid micro methods in the manufacture of sterile products
Discover a risk-based approach to cleaning and disinfection
Delve into case studies of competence in global aseptic manufacturing
Uncover the journey of isolation technology in a large biotech pharmaceutical plant
Analyse the new abilities of robotics and automation through their integration into aseptic technique

Who Should Attend?

Validation Managers
Senior Microbiologists
Senior QA’s and QC’s
Quality Control Managers
Heads of GMP Compliance
Quality Assurance Experts
Technical Operations Leads
Leaders in Sterility Assurance
Cleanroom Managers
Regulatory Affairs Managers
Production Managers
Quality Systems Managers
Heads of Quality Compliance
Process Leaders
Senior Auditors
Bioprocess Research & Development

PLUS – Post-Conference Workshop on 21 September 2022…
Implementation Strategy of Annex 1 in New or Existing Facilities
Led by: Richard Denk, Senior Consultant Aseptic Processing & Containment, Skan AG
View the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL

Pre-Filled Syringes San Francisco
2022-09-19 - 2022-09-20 | Hyatt Centric, Fisherman’s Wharf, San Francisco, CA, 94133, United States
SAE Media Group’s 3rd Annual Conference
September 19 – 20, 2022 | San Francisco, CA, USA
————————————————————————-
The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.

This year’s conference will be assessing the latest developments in new technologies for next generation device design, including computational simulation approaches forming the digital revolution of devices design. Furthermore, the latest advances in digital combination product development will be explored through the lens of lifecycle management and user-centric combination products. Leading experts from big pharma will be presenting case studies on recent advances in platform approaches in drug delivery devices and smart devices, while a panel discussion will explore the emerging opportunities of platforms for injectable devices. With recent developments in industry regulations and guidance, the 2022 agenda will give an international insight into the global regulatory environment and leading FDA representatives will address the key standards to be aware of in injectable device development.
Over recent years we have seen the need for injectable devices to adapt to novel therapeutics. Our expert industry thought leaders will present case studies and updates to the industry’s approach to injectable delivery for novel drug products. Furthermore, our speakers will be assessing the key considerations for primary packaging and CMC approaches to injectable device development.
As part of SAE Media Group’s leading injectable drug delivery portfolio, this event is not to be missed.
The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
To know more visit: http://www.prefilled-sanfrancisco.com/pharmajournalistwl

mRNA Process Development & Manufacturing Summit
2022-09-20 - 2022-09-22 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston, MA this month (September 20 – 22, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing!
This conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data, allowing you to stay ahead of the curve.
If you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription, purification, and analytical validation of your mRNA drug substance, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field.
Multiple functions from 75+ leading companies and their teams have already registered, here’s just a snapchat:

Director – Business Development mRNA Therapeutics
Senior Director – Manufacturing Science & Technology
Head of Quality
Principal Applications Scientist – mRNA
Director – Formulation and Drug Delivery
Principal Scientist – Early Bioprocess
Senior Process Development Associate – mRNA
Group Leader (RNA Reagents) – Production
Downstream Scientist – Technical R&D
Scientist II – Analytical Development
Director – RNA Therapeutics Development R & D
Director – CMC RNA Vaccines Biopharmaceutical Development
Associate Director – Drug Substance
Senior Director – CMC Reg Affairs Regulatory

With very limited passes remaining, register today and be part of the conversation.
To know more visit: https://ter.li/9v5h9k

2nd NSCLC Drug Development Summit
2022-09-20 - 2022-09-22 | Boston, MA (venue TBC)
Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not, most will progress and/or develop resistance to currently available treatments.
NSCLC remains one of the highest tumor indications of unmet clinical need, with prevalence only set to increase. Focusing from late-line through to early-line, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC.
The 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma, biotech and academic leaders to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication.
We will be focusing on:

Refining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting
Investigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery, chemo and/or radiotherapy where applicable, to define therapeutic options with better safety and efficacy outcomes in second line or beyond
Overcoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations
Providing clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients
Identifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options
Exploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria

Join the NSCLC Summit for 3 jam-packed days of presentations, panel discussions and interactive workshops with over 20 expert industry speakers.
There has never been a more important time to rally together to defeat NSCLC and radically change patients lives.
To know more visit: https://bit.ly/3mpftud

Reuters Events: Cell & Gene Therapy USA 2022
2022-09-20 - 2022-09-21 | Virtual
Co-create a commercial toolkit that enables suitable, scalable and sustainable growth.
With over 20 CGTs projected to be approved by 2025, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth, unstable infrastructure, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization.
To realize this potential, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further, transforming our healthcare system to guarantee scalable and sustainable growth.
Don’t get left behind.
Join us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization, readying the world for CGT as a frontline treatment.
To know more visit: https://bit.ly/3oepDP3

Oligonucleotide Therapeutics and Delivery Conference 2022
2022-09-21 - 2022-09-22 | London, UK
Part of the 13th annual RNA Therapeutic series of events
SMi’s 2nd Annual Conference
Oligonucleotide Therapeutics and Delivery Conference 2022
Date: 21st – 22nd September 2022
Location: London, UK
Website: www.oligonucleotide.co.uk/PharmaJournalist
Advancements in extra-hepatic delivery of oligonucleotides
The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.
Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.
Benefits of attending:

Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials
Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity
Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development
Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA
Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics

Plus, two interactive half day pre-conference workshops on 20th September 2022:

Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator, Ritwick Sawakar, MRC Investigator, MRC Toxcology Unit, University Of Cambridge
Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC Consulting

CHAIRS FOR 2022:

Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon
jimmy Weterings, Principal Scientist, AstraZeneca

FEATURED 2022 SPEAKERS INCLUDE:

Shalini Anderson, Vice President Oligonucleotide Discovery,AstraZeneca
Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech
Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen pharmaceuticals
SarahTabrizi,Director of UCL Huntington’s disease centre, UCL Institute of Neurology
Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets
David Evans, Chief Scientific Officer, Sirnaomics
Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator
Bart Anderson,Senior Director of R&D, Exicure

Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers of:

RNA Biology/Discovery
Novel Therapeutic Modalities
Innovation Technologies
C-level Scientific Executives
Formulation and Drug Delivery
Clinical Research and Development
Cell Biology

EARLY-BIRD RATES:

BOOK BY 29TH APRIL AND SAVE £400
BOOK BY 31ST MAY AND SAVE £300
BOOK BY 30TH JUNE AND SAVE £200

Additional Contact Info:
T: +44 (0)20 7827 6154
E: ngaloria@smi-online.co.uk
LinkedIn: SMi Pharma
Twitter: @SMiPharma | #SMiOligonucleotides
Keywords:
Small interfering RNA, siRNA, Antisense therapy, DNA, RNA, nucleic acid, mRNA, Micro RNA, RNA-induced silencing complex, RISC, Aptamers, oligonucleotide, peptide molecules, Immunogenicity, Drug pipeline, short interfering RNA, silencing RNA, RNA interference, RNAi, mRNA degradation
Hashtags:
#SmallinterferingRNA, #siRNA, #Antisensetherapy, #DNA, #RNA, #nucleicacid, #mRNA, #MicroRNA, #RNAinducedsilencingcomplex, #RISC, #Aptamers, #oligonucleotide, #peptidemolecules, #Immunogenicity, #Drugpipeline, #shortinterferingRNA, #silencingRNA, #RNAinterference, #RNAi, #mRNAdegradation

4th RAS-Targeted Drug Development Summit
2022-09-26 - 2022-09-28 | Marriott Burlington, One Burlington Mall Road, Burlington, MA, 01803, United States
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is, in fact, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation.
The 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before, we will unite 300+ experts to showcase 3-days of exclusive, never shared before data as we delve into accelerating discovery and emerging strategies, optimizing translation and pre-clinical development, and advancing the landscape of clinical trials for combinations and monotherapies.
With mounting success in targeted RAS drugs, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need. Through novel data, expert insight, and exclusive discussions with global leaders, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C, G12D, and G12V. Continuing to advance valuable combination therapies into the clinic, and finally, crack resistance to RAS targeted therapeutics.
Access the official agenda for more information.
Early-bird & team discounts available – Secure your place today.

LEAP TA: Life Sciences 2022
2022-10-03 - 2022-10-05 | Embassy Suites by Hilton Boston at Logan Airport, 207 Porter St, Boston, MA, 02128, United States
The Definitive Event to Transform Your Internal Impact & Differentiate Your Employer Brand to Attract the in-Demand Biopharma Talent Required to Fast-Track Business Innovation & Growth
Now in its fourth year, LEAP TA: Life Sciences is the only forum dedicated to helping established and emerging life sciences organizations operating in the US who are breaking away from traditional TA to develop high functioning TA teams bursting to inspire talent needed to drive mission-critical innovation.
It is a unique opportunity to engage in a genuinely disruptive dialogue with your peers around what TA tech tools are really worth the investment and the radical new talent acquisition strategies required to address how life sciences organizations will deal with the fallout of the tight talent market in 2022 and beyond.
Designed for anyone with a stake in talent acquisition at the heart of biopharma businesses of all sizes, those who take part will find out how to rewrite the rules of talent acquisition to balance speed with fit in finding brilliant people to gain a sustainable competitive advantage.
So, whether you work in the newest start-up biotech or the largest big pharma company, there’s something at this event for you. Secure your place now to save time, money and add vital efficiencies to your talent acquisition activities.
To know more visit: https://bit.ly/3HO1Tdv

2nd Rare and Genetic Kidney Drug Development Summit
2022-10-04 - 2022-10-06 | Hilton Woburn, 2 Forbes Road, Woburn, MA, 01801, United States
Uniting industry experts dedicated to accelerating the frontier of transformative therapeutics, the 2nd Rare & Genetic Kidney Disease Drug Development Summit is the definitive industry forum sharing cross-industry insight to understand genetic drivers of disease, uncover early biomarkers of efficacy, and navigate disease specific endpoint development.
From clarifying molecular characteristics to reclassify disease subtypes to enrolling patient cohorts in rare disease populations, join industry experts in-person from Travere Therapeutics, FDA, Sanofi, Chinook Therapeutics, Goldfinch Bio, Takeda, Regulus Therapeutics, Otsuka and many more to accelerate life-changing therapeutics for the treatment of ADPKD, ARPKD, IgA, FSGS, Alport Syndrome.
To know more visit: https://ter.li/rzowfh

4th Macrophage-directed Therapies Summit
2022-10-04 - 2022-10-06 | Crowne Plaza Boston Woburn, 15 Middlesex Canal Park Dr, Woburn, MA, 01801, United States
4th Macrophage-directed Therapies Summit, taking place from 4-6 of October in Boston, will bring together professionals to accelerate the clinical validation of macrophage-directed therapies, manipulating and fixing phenotypic plasticity to develop safe, targeted therapies for oncology, autoimmunity, inflammation and beyond.
Join your peers in person and delve into:

CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery

You can view the event guide here: https://ter.li/ezyi0h
Secure your place at the summit here: https://ter.li/x9p0ua
We are looking forward to welcoming you to Boston this October!

2nd Annual Next Generation Pharmaceutical Cleanroom
2022-10-05 - 2022-10-06 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
2nd Annual Next Generation Pharmaceutical Cleanroom
5 – 6 October 2022
London, UK
http://www.nextgen-pharmacleanroom.com/PJwl
Sponsored by Ecolab, Elis Cleanroom, Innerspace, Microgenetics, Novatek
Co-Chaired by: Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda
Advances in Pharma 4.0 for an Improved, Efficient and Contaminant-Free Cleanroom
SAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.
This one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals, biologicals, and cleanroom industry experts to explore hot topics within cleanroom design and engineering, best practices and regulation, environmental and contamination control, and pharmaceutical microbiology.
In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals, technological advancements in cleanrooms, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market.
This event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible, to the developments in technology that are enabling this to happen. Whether through robotics, automated disinfection, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry.
Event Hashtag: #PharmaCleanrooms
Key Reasons to attend:

Learn how to maximise the latest cleanroom technologies to modernise your contamination control strategy
Maximise the cost-effectiveness of your cleanroom and navigate best practises for cleanroom design
Optimise your preparation for upcoming regulatory changes, including the impending Annex 1
Increase your cleanroom availability & accessibility through streamlined approaches to contamination control

WHO SHOULD ATTEND:
Senior Micro Manager, QC Manager, Quality Director, Clean Room Design Managers, Design, Qualify and Testing – Clean Room (across the board), Head of Clean Room Technologies, Head of Compounding Pharmacies, Head of Clinical Drug Products, Head of Clinical Medical Device
View the brochure and to download visit http://www.nextgen-pharmacleanroom.com/PJwl

SAE Media Group's 3rd Annual Wearable Injectors and Connected Devices Conference
2022-10-10 - 2022-10-11 | London, UK
SAE Media Group’s 3rd Annual
Wearable Injectors and Connected Devices Conference
10 – 11 October 2022 | London, UK
http://www.wearable-injectors.co.uk/Pharmajournalist
The Latest Innovations In Digital Health And On-Body Drug Delivery For The Pharmaceutical Industry
SAE Media Group’s 3rd annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent, high volume and viscous drugs grow.
Benefits of Attending:

Engage with key regulatory updates surrounding digital health and medical devices
Discover advances in device design and development for large volume delivery via on-body injectors
Explore the key drivers of novel drug products for the development for on-body injectors
Hear insights into the growing potential of digital health to improve patient experience and treatment
Develop your understanding of design strategies for connectivity and digital health

Delegates will have the opportunity to network with the following companies:

Johnson & Johnson
Biogen
AstraZeneca
Merck KGaA
Novartis
Novo Nordisk
Boehringer Ingelheim

And many more!!
Who Should Attend:

Executives, Directors, VPs, Heads, Principals, Managers of:
Drug-Delivery Developers
Autoinjectors
Device Engineering
Human Factors
Injectables
Packaging
Regulatory Affairs
Connectivity
Medical Device Data
Novel Product Technology
Smart Device Developers
Device Safety Solution Providers
or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals, biotech, device developers and solution providers.

The two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity, and a platform for exchanging ideas.
For more information contact:
Nikisha Galoria | Marketing Executive | SAE Media Group
Email: ngaloria@smi-online.co.uk
Phone: +44 (0) 20 7827 6164
Follow us on:
LinkedIn: SAE Media Group Pharma
Twitter: @SAEMGPharma

Reuters Events: Pharma 2022
2022-10-11 - 2022-10-13 | Nice Acropolis Convention Center, Nice, France
Comprehensive frameworks for equitable access and accelerated digital transformations are soon to be realized. But progress is slowing, risking a return to the old model plagued by persistent health disparities.
To thrive, each strategy and tactic must be centred with a whole-human approach, ensuring an agile, patient-driven, technology-enabled change.
You must advance intelligent automation, delivering value-driven content that enhance patient and HCP experiences, activate new skillsets for field teams to strengthen clinical practices, whilst collaborating with stakeholders – and competitors – to drastically improve equitable access to the vast galaxy of innovation improving patient outcomes and propelling commercial growth.
Reuters Events: Pharma 2022 (11-13 October, Nice France – formerly eyeforpharma Barcelona) is the only place where patient experts, leading solution providers, and pharma changemakers – from commercial, marketing, medical affairs, patient engagement, market access and RWE – commit to business transformation as the catalyst for maximum patient impact.
To know more visit: https://bit.ly/3xVKqN8

10th IMPACCT Real World Evidence Summit
2022-10-11 - 2022-10-13 | Crowne Plaza Woburn, 15 Middlesex Canal Park Rd, Woburn, MA, 01801, United States
Returning in person for its 10th year anniversary, the IMPACCT: Real World Evidence Summit will deep dive into the use of RWE for regulatory submissions and improved clinical trial design to help you navigate the regulatory landscape.
Following recent FDA and EMA guidelines, this comprehensive industry-led forum will address how drug developers can leverage RWE from beginning to end of study, ensure clinical studies are well-designed, include appropriate protections for their patients and upload data integrity.
Join 100+ senior leaders in RWE, RWD, real world analytics experts & epidemiologists from pharma and biotech to take part in this three day summit with over 18 hours of exclusive content.
To know more visit: https://ter.li/tymfzh

3rd Commercializing Flow Chemistry Summit 2022
2022-10-11 - 2022-10-13 | The Bostonian, 26 North St, Boston, MA, 02109, United States
With the exciting proof-of-concept milestones from Phlow, commitments from global regulatory agencies, and breakthroughs from the likes of AbbVie, AstraZeneca, Merck and BMS, over the last 12 months flow chemistry continues to take off at an exponential rate, further evidenced by the significant investments from CDMOs such as Almac, Corden Pharma, Sterling and Cambrex.
Showcasing the steep progress being made whilst addressing the field’s most front-of-mind challenges to enable the full potential of continuous chemistry to come to fruition, the 3rd Annual Commercializing Flow Chemistry Summit is back to bridge the gap between academic and industry innovation as your only meeting bringing both technical and strategic flow chemistry intelligence under one roof in Boston this October.
Uniting 100+ Process Development, Chemistry & Control, PAT, CMC, Continuous Manufacturing and Engineering experts across biopharma, academia, CDMO and fine chemical & API organizations for the first time in person, this is your prime opportunity to turn flow chemistry into industrial applications and implement advanced process control strategies to ensure product quality and meet regulatory expectations.
For practical takeaways across technical chemical engineering, process development, batch to flow transitions, novel chemistries, scale-up, PAT implementation & more, reduce your development cycle and enhance operational efficiency by attending the 3rd CFC Summit 2022!
To know more visit: https://ter.li/pqcevv

Innate Killer Summit Europe
2022-10-18 - 2022-10-20 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, and Macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through innate cell targeting and engineering.
Seize your chance to network with innate immune trailblazers from the likes of Sanofi, Takeda, Gamida Cell, Glycostem and Bayer and gain a comprehensive overview of candidates to inform your strategic development and progress the field together with an industry brain trust.
Bridging the gap between the technicalities of early discovery through to process optimisation and leaping regulatory hurdles, this is the must-attend meeting to accelerate safe and scalable therapies in Europe.
To learn more, visit: www.innate-killer-europe.com

Process Development for Cell Therapies Summit
2022-10-18 - 2022-10-20 | Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
“The Process is the Product” – Drive Process Excellence at the Only Summit Dedicated to Process Development for Cell Therapies

As momentum continues to build for the cell therapy industry, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods, maximize scalability and achieve regulatory compliance.
Join your peers who will all be gathering to learn how to identify and plug platform gaps for automation, global scale-out, faster phase development, increased affordability, and more!
With 20+ case studies being presented, you will come away with tried and tested strategies informed by industry leaders such as BMS, Kite, Lyell Immunopharma, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy, delivering case studies to provide actionable insights.
Now is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster.
Find out more about the meeting, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/lbtpp0
We look forward to welcoming you to Boston in October!

3rd Annual Gene Therapy Immunogenicity Summit
2022-10-18 - 2022-10-20 | The Colonade, 120 Huntington Ave, Boston, MA, 02116, United States
The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate, measure and predict the immune response to your gene therapy candidate.
In the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays.
Incorporating insights from leading immunological, bioanalytical, and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity.
With 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies.
To know more visit: https://ter.li/acp4lt
